日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

M281, an Anti-FcRn Antibody: Pharmacodynamics, Pharmacokinetics, and Safety Across the Full Range of IgG Reduction in a First-in-Human Study

M281,一种抗FcRn抗体:在首次人体试验中,IgG降低全范围的药效学、药代动力学和安全性

Ling, Leona E; Hillson, Jan L; Tiessen, Renger G; Bosje, Tjerk; van Iersel, Mattheus Paulus; Nix, Darrell J; Markowitz, Lynn; Cilfone, Nicholas A; Duffner, Jay; Streisand, James B; Manning, Anthony M; Arroyo, Santiago

Molecular profiling of rheumatoid arthritis patients reveals an association between innate and adaptive cell populations and response to anti-tumor necrosis factor

对类风湿性关节炎患者的分子谱分析揭示了先天性和适应性细胞群与抗肿瘤坏死因子反应之间的关联

Farutin, Victor; Prod'homme, Thomas; McConnell, Kevin; Washburn, Nathaniel; Halvey, Patrick; Etzel, Carol J; Guess, Jamey; Duffner, Jay; Getchell, Kristen; Meccariello, Robin; Gutierrez, Bryan; Honan, Christopher; Zhao, Ganlin; Cilfone, Nicholas A; Gunay, Nur Sibel; Hillson, Jan L; DeLuca, David S; Saunders, Katherine C; Pappas, Dimitrios A; Greenberg, Jeffrey D; Kremer, Joel M; Manning, Anthony M; Ling, Leona E; Capila, Ishan

Pharmacokinetic equivalence, comparable safety, and immunogenicity of an adalimumab biosimilar product (M923) to Humira in healthy subjects.

在健康受试者中,阿达木单抗生物类似药(M923)与阿达木单抗(Humira)具有药代动力学等效性、可比安全性和免疫原性

Hillson Jan, Mant Tim, Rosano Molly, Huntenburg Carolyn, Alai-Safar Mehrshid, Darne Siddhesh, Palmer Donna, Pavlova Borislava G, Doralt Jennifer, Reeve Russell, Goel Niti, Weilert Doris, Rhyne Paul W, Chance Kamali, Caminis John, Roach James, Ganguly Tanmoy

Comparison of alternative primary outcome measures for use in lupus nephritis clinical trials

比较狼疮性肾炎临床试验中不同的主要结局指标

Wofsy, David; Hillson, Jan L; Diamond, Betty

Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial

阿他西普联合吗替麦考酚酯和皮质类固醇治疗狼疮性肾炎:一项提前终止试验的结果

Ginzler, Ellen M; Wax, Stephen; Rajeswaran, Anand; Copt, Samuel; Hillson, Jan; Ramos, Eleanor; Singer, Nora G